<DOC>
	<DOCNO>NCT01635764</DOCNO>
	<brief_summary>Hidradenitis Suppurativa painful , chronic skin disease characterize recurrent inflame nodule abscess , may rupture form fistulas subsequent scarring . This Study open-label extension study available subject participate prior adalimumab study meet inclusion none exclusion criterion . The purpose study evaluate long term safety , tolerability efficacy adalimumab subject moderate severe HS .</brief_summary>
	<brief_title>Open-label Study Safety Efficacy Adalimumab Treatment Hidradenitis Suppurativa</brief_title>
	<detailed_description>The purpose study evaluate long term safety , tolerability efficacy adalimumab subject moderate severe HS . The clinical trial identifier PIONEER ( OPEN-LABEL EXTENSION ) .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects previously participate prior Phase 3 Abbott HS study : 1 . Completed study ; 2 . Experienced loss response ( LOR ) ; 3 . Experienced Worsening Absence Improvement Prior treatment antiTNF therapy ( e.g. , infliximab , etanercept ) , participation adalimumab trial prior Phase 3 Abbott HS study . Subject receive oral antibiotic treatment HS within 28 day prior Baseline visit , except antibiotic permit prior Phase 3 Abbott HS study . Subject receive oral concomitant analgesic ( include opioids ) HSrelated pain within 14 day prior Baseline visit , except permit analgesic take prior Phase 3 Abbott HS study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hidradenitis suppurativa</keyword>
	<keyword>adalimumab</keyword>
	<keyword>open-label</keyword>
	<keyword>HS</keyword>
	<keyword>acne inversa</keyword>
	<keyword>PIONEER ( OPEN-LABEL EXTENSION )</keyword>
	<keyword>acne</keyword>
	<keyword>tumor necrosis factor</keyword>
	<keyword>boil</keyword>
</DOC>